Compare Ascendis Pharma A/S (ASND) vs Datadog Inc (DDOG) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Datadog (DDOG) trades at $257.54, down 4.25% on the day, with strong technical momentum indicators showing bullish moving averages but overbought RSI readings. The company maintains impressive revenue growth, reaching $3.43B in 2025, with consistent earnings beats in recent quarters. Recent acquisition of Adaptive ML positions DDOG for AI-driven growth, though valuation metrics remain elevated with P/E of 660 and P/S of 25.5.

Outlook remains positive with 83% analyst buy ratings and $246 consensus target, though current price exceeds target. Key risks include high valuation multiples, moderating growth guidance, and competitive pressures in cloud observability. The stock's 88.7% YTD surge suggests much optimism is priced in, requiring continued execution to justify premium valuation.